Pacira BioSciences PCRX
NASDAQ PCRX
$36.49 +0.03 (+0.08%)
At close: Nov 10, 2026 · 4:00 PM EST

Pacira BioSciences (PCRX) Restructuring Costs (2023 - 2024)

Updated

Pacira BioSciences' Restructuring Costs was $1.2 million in Q3 2024, up 500.0% from $200,000 a year earlier and up 20.0% from the prior quarter.

Analysis

Pacira BioSciences (PCRX) Restructuring Costs (2023 - 2024) Analysis & Trends

On a trailing twelve-month basis, Pacira BioSciences' Restructuring Costs was $3.34 million through Sep 30, 2024, up 193.7% year-over-year; for FY2017, it was $51.5 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Pacira BioSciences 1.45 Bn 466.99 Mn 139.42 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 1.20 Mn
Jun 30, 2024 1.00 Mn
Sep 30, 2023 200,000.00
Jun 30, 2023 936,000.00
API Access

Pacira BioSciences Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=PCRX&period=max&api_key=YOUR_API_KEY